HCV: Continuing Advances From Individual Cure to Disease Elimination
Source: HCV: Continuing Advances From Individual Cure to Disease Elimination

Table of Contents

 

Slideset

HCV: Continuing Advances From Individual Cure to Disease Elimination

In this downloadable slideset, Gregory Dore, MBBS, PhD, FRACP, MPH; Graham R. Foster, FRCP, PhD; Ira M. Jacobson, MD; and Norah Terrault, MD, MPH, review strategies for eliminating HCV infection, both at the individual level and at the population level. The slideset includes a review of where the HCV field now stands, from the unprecedented levels of efficacy and simplicity in curing individual patients, through to the steps required to advance toward the goal of eradicating HCV across communities and ultimately throughout the world.
Format: Microsoft PowerPoint (.ppt)
File size: 3.07 MB
Date posted: 12/7/2016
  • Weighing the Treatment Options for Genotype 3 HCV Infection in Cirrhotics

    Mark S. Sulkowski MD - 2/25/2016    3 comments / Last Comment: 4/11/2016
    In my practice, it is the patient with cirrhosis and genotype 3 HCV infection who causes me to pause and carefully consider the patient’s treatment options.
  • Decompensated Cirrhosis: My Take on New Treatment Strategies Following AASLD 2015

    Ira M. Jacobson MD - 12/24/2015    2 comments / Last Comment: 1/4/2016
    Despite the variety of highly effective, highly tolerable regimens available for treating HCV, strategies for patients with decompensated liver disease remain challenging.
  • How I Manage Patients With HCV After DAA Treatment Failure

    Jordan J. Feld MD, MPH - 1/19/2016    6 comments / Last Comment: 6/25/2016
    In the few HCV patients for whom DAA treatment fails, I consider a combination of 2 or more of the following: switching to a different DAA class, treating for longer, or adding ribavirin.
  • How Recent Guideline Updates on HBV Screening in HCV-Infected DAA Recipients Affect Clinical Practice

    Norah Terrault MD, MPH - 11/23/2016    1 comment / Last Comment: 11/29/2016
    How do recent AASLD/IDSA updates on HBV screening change nonspecialist and specialist management of HCV patients? Here’s my take.
  • How Data From the 2016 Boston Hepatology Meeting Will Influence Future HCV Patient Management

    Mark S. Sulkowski MD - 1/31/2017    1 comment / Last Comment: 2/13/2017
    The 2016 hepatology meeting in Boston offered future solutions to some of my most vexing patient challenges.